Payer Evidence · Health Economics · Market Access
Wamukelekile
Welcome, you all the travelers of the world. Uthando Nethemba reads clinical trials and health-policy signals closely — turning them into decision-ready notes on evidence, health economics, and market access.
Latest from the Blog
Continuous Atom Reloading in Neutral-Atom Qubits: A Subsystem Result, Not Yet a Fault-Tolerant One
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a peer-reviewed physics paper describing one subsystem of a neutral-atom quantum computer: how quickly a lost or used-up atomic qubit can be replaced from a reservoir without disturbing the qubits…
Lp(a)HORIZON: A Missed Primary Endpoint, a Press Release, and the Numbers That Are Still Missing
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a corporate topline announcement about a completed cardiovascular outcomes trial in a listed company’s pivotal asset. Every result-layer number below is attributed as a company statement; trial design, population, and…
Two Gates in Heart Failure: A Drug That Bound Its Target and Still Failed, and One That Passed Its Trial and Still Split on Reimbursement
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. This piece covers two separate, publicly documented events in the same disease area: a completed, peer-reviewed phase 2b trial (not a simulation, not a preprint) and two national health-technology-assessment…
Get new content delivered directly to your inbox.
